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Glioblastoma (GBM) is one of the most common and dismal brain tumors in adults. Further
elucidation of the molecular pathogenesis of GBM is mandatory to improve the overall
survival of patients. A novel small non-coding RNA molecule, microRNA (miRNA), appears
to represent one of the most attractive target molecules contributing to the pathogenesis
of various types of tumors. Recent global analyses have revealed that several miRNAs
are clinically implicated in GBM, with some reports indicating the association of miRNA
dysregulation with acquired temozolomide (TMZ) resistance. More recent studies have
revealed that miRNAs could play a role in cancer stem cell (CSC) properties, contributing to
treatment resistance. In addition, greater impact might be expected from miRNA-targeted
therapies based on tumor-derived exosomes that contain numerous functional miRNAs,
which could be transferred between tumor cells and surrounding structures.Tumor-derived
miRNAs are now considered to be a novel molecular mechanism promoting the
progression of GBM. Establishment of miRNA-targeted therapies based on miRNA
dysregulation of CSCs could provide effective therapeutic strategies for TMZ-resistant
GBM. Recent progress has revealed that miRNAs are not only putative biological markers
for diagnosis, but also one of the most promising targets for GBM treatment. Here in, we
summarize the translational aspects of miRNAs in the diagnosis and treatment of GBM.
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INTRODUCTION
Glioblastoma (GBM) is one of the most common and malignant
primary brain tumors in adults (Louis et al., 2007). The recent
introduction of concomitant temozolomide (TMZ) with radio-
therapy has led to prolonged overall survival of GBM patients.
Furthermore, a small subgroup has shown favorable prognosis
with survival exceeding 5 years (Stupp et al., 2009). However,
median overall survival remains around 14.6 months, and the
5-year survival rate is only 9.8% at present (Stupp et al., 2009). In
particular, a methylated O-6-methylguanine-DNA methyltrans-
ferase (MGMT) group showed prolongation of overall survival
from 15.3 to 23.4 months using TMZ. Conversely, an unmethy-
lated MGMT group showed no signiﬁcant beneﬁt with TMZ
(11.8 vs. 12.6 months; Stupp et al., 2009). Further development
of diagnosis and treatment based on novel molecular mecha-
nisms is necessary for GBM patients, particularly for those with
unmethylated MGMT.
A class of small non-coding RNAmolecules, namedmicroRNA
(miRNA), was recently identiﬁed and revealed to regulate a wide
spectrum of gene expression in a post-transcriptional manner
(Ambros, 2004; Bartel, 2004). More than 1500 precursors and
1921 mature Homo sapiens miRNAs have been identiﬁed and reg-
istered in miRBase to date (Kozomara and Grifﬁths-Jones, 2011).
Primary miRNA (pri-miRNA) is transcribed in the nucleus, and
spliced to precursor miRNA (pre-miRNA) by Drosha complexes.
Pre-miRNA is then transferred to the cytoplasm by exportin-5,
followed by further processing for mature miRNA by Dicer com-
plexes. Mature miRNA is incorporated into an effector complex
known as an RNA-induced silencing complex (RISC),which binds
to RNA (mRNA) and can affect the translation and stability of
mRNA (Filipowicz et al., 2008). Expression of the target mRNA is
regulated, either by mRNA cleavage or by translational inhibition,
depending on the complementarity of “seed” sequences (Filipow-
icz et al., 2008; Bartel, 2009). Recent reports have revealed that
miRNAs play crucial roles in tumorigenesis, angiogenesis, inva-
sion, and apoptosis in various types of tumor (Ambros, 2004;
Bartel, 2004; Figure 1). In addition, miRNA expression proﬁling
may yield more accurate classiﬁcations of human cancers than
mRNA expression proﬁling (Lu et al., 2005). The present review
summarizes the clinical implications ofmiRNA inGBMand future
directions of miRNA-based therapy for GBM.
IDENTIFICATION OF GLIOMA-RELATED miRNA
Calin (2002) provided the ﬁrst report of the frequent deletions
and down-regulation of miR-15 and miR-16 at chromosome
13q14 in a majority of cases of chronic lymphocytic leukemia,
and also demonstrated that more than half of miRNA genes are
located in cancer-associated genomic regions or in fragile sites
(Calin, 2004). In addition, Lu et al. (2005) reported that the
classiﬁcation of malignant tumors based on miRNA expression
proﬁles was more precise than that based on mRNA expres-
sion proﬁles. These ﬁndings have added impetus to miRNA
research in the ﬁeld of oncology. In 2005, two reports identiﬁed
aberrant miRNA expression in GBM using microarray analy-
sis (Chan et al., 2005; Ciafre et al., 2005). A common miRNA
identiﬁed by both groups, miR-21, has been revealed to act as
an anti-apoptotic factor (Chan et al., 2005; Papagiannakopou-
los et al., 2008). Indeed, miR-21 represents a unique miRNA
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FIGURE 1 | Concept of microRNA-targeted therapy. Expression of
target genes is negatively regulated by microRNA (miRNA) via mRNA
cleavage or translational inhibition. Therefore, miRNA acts as oncogenic
miRNA when the target genes are tumor suppressor genes, and as
tumor-suppressive miRNA when the target genes are oncogenes. Through
regulation of tumor-related genes, miRNA could activate speciﬁc signaling
pathways. A single miRNA could regulate expression of multiple genes, so
the functions of miRNA are varied, affecting cancer stem cell
properties, tumor proliferation, apoptosis, invasion, and angiogenesis.
miRNA has the potential to play roles in tumorigenesis, malignant
transformation, and treatment resistance. Theoretically, there are two
approaches to miRNA-targeted therapy: inhibition of oncogenic miRNA with
antago-miRs; and replacement of tumor-suppressive miRNA with miRNA
mimics.
overexpressed in almost all types of tumor investigated to date.
In addition, a recent in vivo study revealed that miR-21 plays
a critical role in various steps of tumor progression (Medina
et al., 2010). This study also proved for the ﬁrst time that cer-
tain tumors addict to speciﬁc miRNAs. The concept of “oncomiR
addiction,” similar to the phenomenon of “oncogenic addic-
tion,” would also facilitate study of the therapeutic application
of miRNAs in human cancer. Two studies using microarray
analysis subsequently identiﬁed miR-128 andmiR-10b, and inves-
tigated the biological function of these miRNAs (Godlewski et al.,
2008; Sasayama et al., 2009). The stem-loop reverse transcription-
polymerase chain reaction (RT-PCR) array, which can evaluate
miRNA expression with superior sensitivity and speciﬁcity to
microarrays, has been applied to investigations using miRNA pro-
ﬁling (Chen et al., 2009; Mestdagh et al., 2009). Our previous
study using the array identiﬁed 16 miRNAs for which expression
was signiﬁcantly altered in GBM (WHO grade 4) compared with
anaplastic astrocytoma (WHO grade 3), and demonstrated that
overexpression of miR-196a/b correlates with shorter overall sur-
vival (Guan et al., 2010). Malzkorn et al. (2010) also identiﬁed
12 upregulated miRNAs involved in the malignant progression
of gliomas using stem-loop real-time RT-PCR. Kim et al. (2010)
also reported clinical implications of miR-26 gene ampliﬁcation
in GBM patients using TCGA data. Rao et al. (2010) recently used
a locked nucleic acid array to generate a large-scale, genome-wide
miRNA expression proﬁle, and identiﬁed 55 upregulated and
29 downregulated miRNAs in malignant gliomas. A more
important ﬁnding in the study was that a cluster of only 23
miRNAs was sufﬁcient to distinguish GBM from anaplastic
astrocytoma with 95% accuracy (Rao et al., 2010). Further-
more, Srinivasan et al. (2011) identiﬁed a 10-miRNA expression
signature that could predict overall survival of GBM patients.
More recently, a combined mRNA and miRNA expression proﬁl-
ing signature has been used to identify ﬁve GBM subclasses (Kim
et al., 2011).
Dysregulated miRNAs, as identiﬁed by recent global studies
for GBM, were summarized in our previous review (Mizoguchi
et al., 2012). Each report has demonstrated several miRNAs for
which expression was signiﬁcantly altered in GBM compared with
normal brain tissues or lower-grade gliomas. Taken together, 52
upregulated miRNAs and 33 downregulated miRNAs have been
reported in seven global studies published between 2005 and 2010
(Mizoguchi et al., 2012). The results of each report were quite
varied. One of the causes of such discrepancies is differences in
methodology, platform, and control samples. Recurrent aber-
rations of expression were thus detected in only four miRNAs
(miR-21, miR-10b, miR-128-1, and miR128-2). In fact, recently
identiﬁed miRNAs have not been included in previous studies,
but the number of concordances among these studies is extremely
small. It is obvious, however, that these four miRNAs have the
potential to contribute to the molecular pathogenesis of GBM
(Table 1).
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Table 1 | Candidate targets of miRNA in glioblastoma.
miR-21 Most common oncomiR in a wide range of cancers, acting as an anti-apoptotic factor targeting a network of p53, transforming growth
factor beta (TGF-β), and mitochondrial apoptosis tumor suppressor genes
miR-10b Commonly upregulated miRNA in glioblastoma, located in HOX cluster
miR-128 miRNA associated with glioma stem cell properties and neuronal differentiation via Bmi-1 and epidermal growth factor receptor
(EGFR)/platelet-derived growth factor (PDGF)/AKT signaling pathways
miR-34b One of the most elucidated tumor suppressor miRNAs, considered a key regulator of tumor suppressor pathways; one of the promising
targets for miRNA replacement therapy
miR-196 Extremely highly expressed miRNA in glioblastoma showing signiﬁcant association with overall survival
SUBCLASSIFICATION BASED ON miRNA EXPRESSION
PROFILES
Based on molecular pathological perspectives, GBM is a heteroge-
neous tumor. To elucidate novel therapeutic approaches, therefore,
more precise stratiﬁcation is necessary. Recent integrated genomic
analyses have allowed molecular subclassiﬁcation of GBM based
on gene expression proﬁles (Phillips et al., 2006; Verhaak et al.,
2010; Huse et al., 2011). Two recent classiﬁcations based onmRNA
expression proﬁles have been reported, with both identifying one
of the subclasses as showing an expression signature resembling
that of a “proneural” precursor cell (Phillips et al., 2006; Verhaak
et al., 2010). However, the other subclasses of GBM have shown
little association with neural differentiation, and disagreement
remains regarding the relationship of subclasses to clinical out-
comes (Phillips et al., 2006; Verhaak et al., 2010). Establishment
of more efﬁcient diagnostic and therapeutic strategies based on
molecular stratiﬁcation is a focus of current research.
Recent attempts at miRNA expression proﬁling may indicate
the way toward more accurate classiﬁcation of human cancers
thanmRNA expression proﬁling (Lu et al., 2005). Kim et al. (2011)
identiﬁed ﬁve clusters of GBM based on miRNA expression pro-
ﬁles, which appeared to predict clinical outcomes more precisely
than mRNA proﬁle. Expression proﬁles of miRNA could lead to
the identiﬁcation of novel therapeutic targets based on clinically
useful subclassiﬁcations of GBM. Recent reports, however, have
identiﬁed signiﬁcant associations between miRNA and mRNA
expression signatures (Wuchty et al., 2011; Ma et al., 2012b). Fur-
ther clariﬁcation of the physical interactions between miRNA and
mRNA is necessary for more precise and practical stratiﬁcation
of GBM.
PROGNOSTIC VALUE OF miRNA EXPRESSION PROFILES
We recently revealed that expressions of miR-196a and miR-196b
are extremely high compared with other overexpressedmiRNAs in
GBM (Guan et al., 2010). Furthermore, we identiﬁed a signiﬁcant
association between high expression of miR-196a/b and shorter
overall survival among GBM patients, so both of these miRNAs
are considered to be associated with themalignant transformation
of gliomas (Guan et al., 2010). Overexpression of miR-196 has
also been identiﬁed in several other cancers (Gaur et al., 2007),
and Bloomston et al. (2007) reported a correlation between miR-
196a-2 and shorter overall survival in patients with pancreatic
cancer. Another recent report validated the prognostic value of
miR-196b in a large cohort of GBM(Ma et al., 2012a). As described
above, Kim et al. (2011) also identiﬁed ﬁve clusters of GBM based
on miRNA expression proﬁles, predicting clinical outcomes more
precisely than mRNA proﬁles. In addition, a 10-miRNA signature
was identiﬁed to predict survival of GBM patients using TCGA
data (Srinivasan et al., 2011). Expression proﬁles of miRNA are
useful for predicting GBM patient survival, and have the potential
to identify efﬁcacious therapeutic targets.
miRNA EXPRESSION ASSOCIATED WITH TMZ RESISTANCE
Since the introduction of TMZ as standard chemotherapy, con-
comitant TMZand radiotherapy have improved both progression-
free and overall survival in patients with GBM (Stupp et al.,
2005). However, the clinical prognosis of patients with GBM
remains poor, with a median overall survival of only 14.6 months
(Stupp et al., 2005). Furthermore, molecular-targeted therapy
for single genes could not achieve prolonged overall survival of
GBMpatients (Weller et al., 2012). Furthermolecularmechanisms
underlying treatment resistance need to be elucidated for malig-
nant gliomas, and miRNA offers an attractive molecular target to
improve the effects of conventional therapies.
In fact, recent miRNA studies have revealed that aberrant
miRNA expression could affect chemosensitivity, and have also
identiﬁed several miRNAs (i.e., miR-21, miR-125b-2, miR-195,
miR-455-3p, miR-10a) associated with TMZ resistance (Shi et al.,
2010; Ujifuku et al., 2010; Zhang et al., 2012). Recent reports
have demonstrated that TMZ-induced apoptosis is inhibited by
miR-21 overexpression by decreasing the Bax/Bcl-2 ratio and
caspase-3 activity in GBM cell lines (Shi et al., 2010; Zhang et al.,
2012). Ujifuku et al. (2010) also identiﬁed three miRNAs (miR-
195, miR-455-3p, and miR-10a*) overexpressed in the induced
TMZ-resistant cell line, and demonstrated that miR-195 inhi-
bition enhanced TMZ-induced cell death. All of these reports
indicated that miRNAs play a role in TMZ resistance, and regu-
lation of the speciﬁc miRNA combined with TMZ could enhance
TMZ-induced cell death. As described above, speciﬁc miRNAs
are involved in critical signaling pathways of GBM (Sana et al.,
2011), so the regulation of aberrant miRNA expression could
affect not only conventional radio- and chemosensitivity, but
also sensitivities to molecular-targeted therapy. The combination
of miRNA-targeted therapy and conventional chemotherapy or
molecular-targeted therapy has the potential to enhance treatment
efﬁcacy, particularly for patients with TMZ-resistant GBM.
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miRNA EXPRESSION ASSOCIATED WITH RADIORESISTANCE
Radiotherapy is another effective cytotoxic therapy for GBM
patients. In 2007, Weidhaas et al. (2007) ﬁrst demonstrated the
association of overexpression of the let-7 family of miRNAs and
radiosensitive state in vitro in lung cancer cells and in vivo in C.
elegans. Thereafter several reports revealed that miRNA dysregu-
lation also affect the radiosensitivity of glioma cells (Chen et al.,
2010; Lee et al., 2011; Li et al., 2011; Gwak et al., 2012). In addi-
tion, global gene expression proﬁle revealed that ionizing radiation
induced signiﬁcant alterations of miRNA expression in tumor
cells (Niemoeller et al., 2011). Several miRNAs are associated with
DNA double-strand breaks (DSBs) repair system including non-
homologous end joining (NHEJ) and homologous recombination
(HR). For instance, a catalytic subunit of DNA-dependent pro-
tein kinase (DNA-PKs) is inhibited by miR-7 and miR-101 (Yan
et al., 2010; Lee et al., 2011), and ataxia telangiectasia mutated
protein (ATM) is regulated with miR-18a, miR-100, miR-101,
and miR-421 (Ng et al., 2010; Yan et al., 2010). The regulation of
DSBs repair system by miRNA replacement could provide a novel
way to increase vulnerability to radiotherapy. MiR-21, commonly
upregulated in GBM, also play a crucial role for radiosensitization
of GBM by modulating a tumor suppressor network and phos-
phoinositide 3-kinase (PI3K)/AKTpathway (Papagiannakopoulos
et al., 2008; Gwak et al., 2012). Further evaluation of miRNA asso-
ciated with cancer stem cell (CSC) properties is also required,
because CSCs contribute enhanced radioresistance due to greater
activation of DNA-repair responses (Bao et al., 2006).
miRNA AND CANCER STEM CELL PROPERTIES
The CSC hypothesis, that tumors are driven by a small subpopu-
lation of tumor cells with stem cell-like properties, may provide
novel insights into the radio- and chemoresistance of GBM(Magee
et al., 2012). Based on this hypothesis, some therapies in which
tumors show reduced diameter might not be associated with
improved rates of cure if CSCs fail to be eliminated, and ther-
apies targeting CSCs should thus prove clinically more effective
(Reya et al., 2001; Bao et al., 2006). Elucidating themolecular biol-
ogy of CSCs thus appears crucial for resolving the mechanisms
underlying treatment resistance.
Recently, some miRNAs have been reported to contribute to
CSC properties and cancer heterogeneity. Godlewski et al. (2008)
identiﬁed down-regulation of miR-128 in GBM compared with
adjacent brain, leading to reduced self-renewal of glioma stem
cells via Bmi-1 down-regulation. That report represented the ﬁrst
demonstration of an association between miRNA and stem cell
properties in glioma. In addition to miR-128, miR-124, miR-
137 (Silber et al., 2008), miR-34a (Li et al., 2009; Guessous et al.,
2010), and miR-326 (Kefas et al., 2009) reportedly play roles in
the maintenance of CSC properties. The identiﬁcation of miR-
NAs thus adds another mechanism of gene expression associated
with gliomagenesis and maintenance of CSC properties via the
regulation of targeted signaling pathways (Figure 1).
NOVEL TREATMENT STRATEGY BASED ON miRNA
SIGNATURE
Dysregulation of miRNA expression has the potential to affect not
only conventional radio- and chemotherapy, but also sensitivity
to molecular-targeted therapy. Further study of miRNA function
in CSCs may lead to novel treatment strategies for GBM. Con-
sideration of the therapeutic application of miRNAs suggests two
putative options: inhibition of oncogenic miRNAs; and replace-
ment of tumor-suppressive miRNAs (Figure 1). Application of
an antagonist of speciﬁc miRNAs (oncomiR), which would func-
tion as an oncogene, is one way of inhibiting oncogenic signaling
pathways. Another is replacement therapy with mimics of miR-
NAs, to act as tumor suppressors. For both approaches, better
delivery systems to target tissue remain under investigation. Mul-
tiple steps remain to achieve the targeted miRNA-based therapy.
Inhibition of oncogenic molecules has been considered a more
theoretically feasible approach. Considering replacement therapy,
however,miRNA-based therapy could bemore practical than con-
ventional gene therapy, since miRNA is substantially smaller and
more stable than protein-coding genes. Further elucidation of
tumor suppressor miRNA thus has the potential to yield opportu-
nities to develop replacement molecular therapies, which have not
previously been considered as a realistic approach. In fact, recent
research has facilitated the replacement of miRNAs for tumor
suppressor miR-7, miR-128, and miR-34a over the inhibitory
approach (Godlewski et al., 2008; Kefas et al., 2008; Bader, 2012).
As a well-elucidated tumor suppressor miRNA for various types
of tumors, miR-34a is now one of the most promising targets
of miRNA replacement therapy (Bader, 2012). miR-34a, which
is induced by p53, is considered to be a key regulator of tumor-
suppressive signaling pathways in various cancers (Bader, 2012).
Furthermore, recent reports have revealed that miR-34a plays a
crucial role in themolecular pathogenesis of GBM (Li et al., 2009),
although the function ismore complex inGBMand remains under
investigation (Genovese et al., 2012; Silber et al., 2012; Yin et al.,
2012). Replacement therapy of miR-34a is an attractive approach
for various malignant tumors, but should be introduced carefully
for GBM.
Many obstacles must still be overcome to establish miRNA-
targeted therapies. One of the most critical issues is how to deliver
the agent (an miRNA mimic or inhibitor) to brains protected by
the blood–brain barrier. Local delivery techniques could poten-
tially improve the efﬁcacy for GBM, since systematic metastasis
is extremely rare in GBM compared with other types of tumor.
Convection-enhanced delivery (CED) is one of the most promis-
ing local delivery techniques to improve the efﬁcacy of recent
treatments, including conventional chemotherapy, molecular-
targeted therapy, and gene therapy (Zhou et al., 2012). For further
improvement of CED, a nanoparticle delivery system should be
introduced for the treatment of brain tumors (Hadjipanayis et al.,
2010). These approaches would also provide the chance to create
new delivery strategies for miRNA-based therapy.
Tumor-derived exosomes and secreted miRNA are novel and
exciting targets for miRNA-based therapy. Recent investigations
have revealed that exosomes secreted by tumor cells contain
numerous functional miRNAs (Valadi et al., 2007), which could
play important roles in tumor initiation and progression. Secreted
miRNAs derived from tumor cells may play important roles
in intercellular communication, since miRNA transferred from
tumor cells could regulate protein expression in the surrounding
structure (Katakowski et al., 2010). This intercellular mechanism
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represents a novel therapeutic target for the future, and a
recent investigation into the biological function of exosomes sug-
gests the opportunity to create a new miRNA delivery system
(Alvarez-Erviti et al., 2011).
CONCLUSION
As a novel molecule, miRNAmay contribute to TMZ resistance in
GBM and could offer a crucial biomarker not only as a diagnostic
marker, but also as a target for molecular therapies. Thera-
pies based on miRNA could achieve modest changes for more
global gene expression, andmay prove more effective than current
molecular-targeted therapies, which target single protein-coding
genes within an oncogenic signaling pathway. Molecular-targeted
therapy based on miRNA expression proﬁles in CSCs has the
potential to allow development of more radical treatment strate-
gies in the future. Further investigation of miRNAbiology inGBM
could provide novel insights for the development of efﬁcient treat-
ment strategies, especially for TMZ-resistant GBM. Furthermore,
investigations into tumor-derived exosomes are providing some
of the most promising approaches for creating novel strategies for
the diagnosis and treatment of GBM.
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